U.S., Oct. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07904507) titled 'A Comparison of Beta-blockers and Calcium Channel Blockers in Atrial Fibrillation' on Oct. 22.
Brief Summary: Beta-blockers are generally prescribed for the treatment of atrial fibrillation. Their purpose is to slow the heart rate and thereby reduce the workload on the heart. However, beta-blockers can affect patients' quality of life, for example by reducing physical performance or causing fatigue in daily life.
In this study, we aim to determine whether calcium channel blockers can improve the treatment of atrial fibrillation and have a positive impact on the quality of life of patients with atrial fibrillation compared with beta...